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Abstract: Autoimmune hemolytic anemia (AIHA) is increasingly observed after allogeneic
hematopoietic stem cell transplantation (allo-HSCT), with a reported incidence between 4% and
6%. The disease is generally severe and refractory to standard therapy, with high mortality, and
there are neither defined therapies, nor prospective clinical trials addressing the best treatment.
Most of the knowledge on the therapy of AIHAs derives from primary forms, which are highly
heterogeneous as well, further complicating the management of post-allo-HSCT forms. The
review addresses the risk factors associated with post-allo-AIHA, including unrelated donor, the
development of chronic extensive graft-versus-host disease, CMV reactivation, nonmalignant
diagnosis pre-HSCT, and alemtuzumab use in conditioning regimens. Regarding therapy, we
describe standard treatments, such as corticosteroids, intravenous immunoglobulin, splenectomy,
rituximab, cyclophosphamide, and plasma exchange, which have lower response rates than those
reported in primary forms. New therapeutic options, including sirolimus, bortezomib, abatacept,
daratumumab and complement inhibitors, are promising tools for this detrimental complication
occurring after allo-HSCT.
Keywords: autoimmune hemolytic anemia, allogeneic hematopoietic stem cell transplantation,
rituximab, sirolimus and abatacept, bortezomib and daratumumab
Introduction
Autoimmune hemolytic anemia (AIHA) is due to increased destruction of red blood
cells (RBC) mainly driven by autoantibodies and complement (C), but also to other
immune players (activated macrophages, T-lymphocytes, and cytokines).1 The
disease is highly heterogeneous, from mild/compensated to life-threatening forms.
The major determinants of this variability are the class, thermal amplitude and
ability to activate complement of autoantibodies, along with the bone marrow
compensatory activity. AIHA is classified into warm (wAIHA) and cold (cAIHA)
according to antibody characteristics and this distinction has important therapeutic
implications. AIHA is also defined as primary (50% of cases) or secondary,
depending on the presence of an underlying or associated disease (infections,
autoimmune diseases, drugs, malignancies, particularly lymphoproliferative
disorders).2–5
In recent years, there is accumulating evidence about AIHA arising after allogeneic
hematopoietic stem cell transplantation (allo-HSCT), with a reported incidence between
4% and 6%.6–8 The diagnosis of post-allo-HSCT AIHA is challenged by several
concomitant factors, including disease relapse, graft failure, drug- and treatment-related
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toxicity, infection, and graft-versus-host disease (GVHD). In
addition, the cornerstone of AIHA, ie, the direct antiglobulin
test (DAT), may be positive for alloantibodies, with associated
delayed hemolytic transfusion reactions, or for isohemagglu-
tinins produced by donor-derived immunocompetent lympho-
cytes in case of minor ABO-incompatibility (“the passenger
lymphocyte syndrome”).9
Most of the knowledge on therapy of AIHA derives
from retrospective/observational studies with few prospec-
tive trials, mostly in primary forms.10–14 There is no
defined therapy for post-allo-AIHA, with the exception
of clinical experience and expert recommendations, all
underlining the significant morbidity and mortality of
these forms and the consequent need for prompt and
aggressive treatment.
Here, we will review the clinical features of post-allo-
AIHA and the risk factors associated with its occurrence. In
addition, we will describe standard treatments, such as corti-
costeroids, intravenous immunoglobulin (IVIG), splenectomy,
rituximab, cyclophosphamide, and plasma exchange, along
with new therapeutic options, including sirolimus, bortezomib,
abatacept, daratumumab and complement inhibitors.
General concepts of AIHA
AIHA is diagnosed by the demonstration of anti-erythrocyte
antibody through the DAT, and classified according to the
class and thermal range of the autoantibody in wAIHA
(typically DAT+ for anti-IgG, or IgG plus C), cAIHA (due
to IgM with DAT+ for C3d), mixed (DAT+ for both IgG and
high titer cold agglutinins) or atypical forms (DAT negative,
IgA and warm IgM driven). Of note, about 5–10% of AIHAs
remain DAT negative even after performing highly sensitive
tests. In these cases, the diagnosis is made in exclusion after
extensive diagnostic re-evaluation, possibly causing detri-
mental delay in therapy.1 In wAIHA, hemolysis is mainly
extravascular (lymphoid organs, spleen) and mediated by the
Fc fragment of IgG (antibody-dependent cellular cytotoxi-
city), andminimally due to complement coating. At variance,
in cold forms, RBC destruction is mainly driven by comple-
ment activation and RBC coating, with erythrocyte destruc-
tion occurring directly in the circulation and/or in the liver by
activated macrophages. wAIHAs are the most common
forms, with percentages ranging from 60% up to 80% of all
cases, cAIHA accounts for 15% of patients, and the remain-
ing cases have mixed features. Up to 11% of patients with
chronic lymphocytic leukemia and 2–3% of those with non-
Hodgkin lymphoma will develop AIHA at some point in
their disease course.
Considering primary AIHA, usually considered a benign
disease, it should be underlined that about 20% of cases
(mainly warm IgG+C, cold, mixed, and atypical) display
relapsing/refractory features and increased risk of thrombotic
events, representing a clinical challenge. Their reported mor-
tality is 11%, and predictors of a fatal outcome are severe
infections, particularly in splenectomized cases, acute renal
failure, Evans syndrome (concomitant thrombocytopenia),
and multitreatment (4 or more therapy lines).15,16 Figure 1
highlights the rate of the main complications and risks factors
for fatality in primary AIHAs, and Table 1 shows the main
hematologic parameters according to AIHA serologic sub-
types in the largest series reported, highlighting the great
heterogeneity of the disease.15,16
Regarding therapy, steroids are the standard first-line
therapy for wAIHA with a response in 75–80% of patients,
but with an estimated cure rate in 20–30% only.1,2,16 At
variance, steroids are much less effective in cAIHA (15–
30% of cases), and unacceptably high doses are usually
required. Rituximab has become the preferred second-line
choice for steroid-refractory wAIHA, with an overall
response rate of about 80%, a relapse-free survival of ~60%
at 3 years, and amedian time to response of approximately 3‒
6 weeks (range 2‒16).1–3 Rituximab is now recommended as
first-line in cold forms given their poor response to steroids.
In fact, in cAIHA rituximab induced a response in about 50%
of cases (mostly partial responses), with a median duration of
<12 months. For those relapsed after a first course of ritux-
imab, the association with bendamustine or fludarabine is a
reported option.5 Splenectomy is considered the most effec-
tive second-line treatment of primary wAIHA (characterized
by extravascular hemolysis in the spleen) with responses in
more than 80% of cases, and the curative rate 20–50%,
whereas it is contraindicated in cold agglutinin disease
(where hemolysis in mainly intravascular or extravascular
in the liver).1,5 Classic immunosuppressants (azathioprine,
cyclophosphamide, cyclosporine) are progressively moving
to the third line, due to their toxicity a limited efficacy (about
60% of cases in association with steroids).1–3,5,15,16 Table 2
summarizes available therapies for primary warm and cold
AIHAs, and for the most common secondary forms.
Clinical features and risk factors of
post-allo-HSCTAIHA
The first studies reporting the occurrence of AIHA post-
allotransplant appeared in the literature about 10–15 years
ago. A study by Sanz et al17 described 12 patients with severe
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AIHA (eight with cold and four with warm antibodies)
occurring at a median time of 147 days (range, 41–170).
These cases were observed among 272 adult patients with a
variety of malignant hematopoietic disorders transplanted
between 1996 and 2004. Multivariate analysis showed that
HSCT from unrelated donors (P=0.02) and the development
of chronic extensive GVHD (P=0.018) were the only inde-
pendent factors associated with AIHA. Most patients
received steroids as primary treatment for AIHA with no
response in the majority of cases. Two patients were treated
with rituximab and achieved partial response, with an
improvement in transfusion requirements. The mortality
rate was elevated, with 2 patients only still alive at the time
of analysis. AIHAwas never the primary cause of death but
increased morbidity in patients with other concomitant
complications. In line with these findings, Holbro et al9
reviewed the several small series and case reports of various
autoimmune complications following allo-HSCT, including
90 cases of AIHA with a reported mortality of about 60%.
The authors firstly recommended the prompt administration
of systemic steroids, and in case of no response, addition of
rituximab with or without cyclophosphamide, along with
IVIG.
In 2015, Wang et al6 reported 19 cases of AIHA (overall
incidence, 3.6%) among 533 patients who received allo-
geneic HSCT at King’s College Hospital in London. The
median time from HSCT to AIHA was 202 days, and in 3
cases, the onset of AIHA was preceded by an infective
episode (adenovirus, Cytomegalovirus (CMV), and pneumo-
nia of undetermined etiology). The analysis of risk factors
Systemic complications:
Evans syndrome
Sepsis
DIC
Brain: Stoke
Lungs: Pneumonia,
pulmonary embolism
Heart: Cardiac ischemia
Kidney: Acute renal
failure
DVT
Thrombosis (111-20% of cases,mostly in
lgG+C wAIHA, mixed and atypical, and
associated with:
•Hb levels<6 g/dL at onset
•Inteavascular hemolysis
•Previous splenectomy
•Evans syndrome (HR 8, 95% CI 2.5-26)
•Acute renal failure (HR 6.3, 95% CI 1.4-29)
•Infections (HR 4.8, 95% CI 1.5-15)
•Multi-treatment (4 or more lines of therapy)
Hazard risks for AIHA-related death15
Figure 1 Main complications and risks factors for fatality in primary AIHAs. AIHAs show great clinical heterogeneity, including symptoms related to anemia, thrombotic
events, infectious complication, acute renal failure, and circulatory disabling symptoms (typical of cold AIHA).
Abbreviations: DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; AIHA, autoimmune hemolytic anemia.
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showed that unrelated donor and concordant gender between
the donor and the recipient were associated with the occur-
rence of AIHA, with a hazard risk of 5.28 (P=0.026) for the
former, and of 3.52 (P=0.045) for the latter. No significant
association was observed for the following variables: recipi-
ent gender, primary hematological disease, source of hema-
topoietic stem cells, conditioning regimen (alemtuzumab/
ATG versus non-alemtuzumab/ATG, and reduced intensity
versus myeloablative), HLA mismatch between donor and
recipient, ABO antigen mismatch, recipient CMV status, and
concurrent chronic GVHD. At the onset of AIHA, half of the
patients were receiving immunosuppressive therapies, either
as GVHD treatment or prophylaxis. In the majority of
patients, multiple treatments were required, with only half
of cases achieving complete resolution of AIHA. Patients
with post-transplantation AIHA had a higher overall mortal-
ity (hazard risk 2.48; 95% CI, 1.33–4.63; P=0.004). At
variance with previous finding, in this series, 36% of cases
(4 of 11 cases) of deaths were directly attributable to AIHA.
In the same years, risk factors for post-allo-HSCT
AIHA have been analyzed in 265 children (median age
5.1 years, range 0.5–15.4) transplanted between 1998 and
2015 in Taiwan.18 The authors identified 15 cases (inci-
dence 6%), of whom 3 with concomitant thrombocytope-
nia. The median time to emergence of AIHAwas 149 days
(range 42–273), and patients with thalassemia had a higher
rate of AIHA than patients other than thalassemia (11.5%
vs 3.2%; P=0.017). At the onset of AIHA, all patients
were receiving immunosuppressive therapies, either as
GVHD treatment or prophylaxis. All cases were treated
with high dose methylprednisolone and IVIG, and 9
received rituximab. Resolution of AIHA was observed in
12/15 cases (80%) and death in one. No splenectomy was
performed.
More recently, risk factors for post-allo-AIHA have
been investigated in a pediatric population of 531 children
transplanted at Leiden University Medical Center between
2000 and 2016.8 Twenty-six were complicated by autoim-
mune disorders (cumulative incidence 5%), of whom 12
AIHA (46%). Nonmalignant diagnosis pre-HSCT (HR,
3.5; P = 0.031), CMV reactivation (HR, 3.4; P = 0.02),
and alemtuzumab use (HR, 2.5; P = 0.028) were identified
as independent risk factors for autoimmune complications.
Gender, donor type, stem cell source, conditioning regi-
men, T cell depletion, GVHD prophylaxis, ATG serother-
apy pre-HSCT, ABO match, HLA mismatch, acute and
chronic GVHD, EBV reactivation, adenovirus infection/
reactivation, platelet recovery, absolute neutrophil countTa
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recovery, and chimerism in peripheral blood mononuclear
cells were not associated with autoimmune complications.
Patients were treated with corticosteroids and IVIG with
responses in about one-third of cases only. Further thera-
pies were rituximab, bortezomib, or sirolimus, with asso-
ciated resolution in 40%, 57%, and 100% of cases,
respectively. The same authors investigated several immu-
nological parameters in post-transplant patients with or
without autoimmune complications. The former group
has a significantly lower CD3+CD8+ T cell count
(P=0.002), whereas other subsets (CD3+CD4+ T cells,
CD19+CD20+ B cells, CD3−CD16/56+ natural killer
cells, and CD3+TCRγδ+) cells did not differ significantly
between patients with or without autoimmunity. IL-4,
eotaxin, platelet-derived growth factor, and RANTES
were reduced in autoimmune cases, whereas IL-2, IL-6,
IL-16 were increased. Finally, several Th2/Th 1 ratios (IL-
5/interferon (IFN)-γ, IL-5/tumor necrosis factor (TNF)-α,
IL-5/IL-12, IL-6/IFN-γ, IL-6/TNF-α, IL-13/IFN-γ, IL-13/
TNF-α, IL-13/IL-12, and IL-10/TNF-α) pinpoint that auto-
immune complications arise in a Th2-mediated context.
In 2018, a large Spanish collaborative study in adults
and children reported 60 cases of AIHA among 4099 allo-
HSCT between 2000 and 2015 (cumulative incidence
1.5%).7 AIHA occurred at a median of 6 months after
the transplant, and HLA mismatch donor (P=0.005), cord
blood use (P=0.005), and age <15 years (P=0.005) were
associated with its development. Median lines of treatment
were 3 (range 1–7), including corticosteroids (88%),
immunoglobulins (63%), and rituximab (67%). Complete
resolution of AIHA was achieved 55% of cases, and the
cumulative incidence of AIHA-related mortality was 17%.
Table 3 summarizes risk factors available in the literature.
Finally, in a recent large pediatric study investigating
442 patients who underwent HSCT, an autoimmune com-
plication was observed in 20 cases, including 9 AIHA, 6
multilineage cytopenias, 3 immune thrombocytopenias,
and 2 autoimmune neutropenias. These patients were sig-
nificantly older than the control group without autoim-
mune complications (8.2±7.3 years vs 4.0±4.7 years,
P=0.030), and less frequently developed chronic GVHD
(5% vs 26%, P=0.048). There was no significant differ-
ence in gender, source of stem cells, ABO compatibility,
anti-lymphocyte serotherapy, GVHD prophylaxis, prior
donor lymphocyte infusion, total body irradiation, pre-
transplant autoimmunity or prevalence of acute GVHD.190
Current treatments of post-allo-
HSCTAIHA
Treatment of AIHA after HSCT is challenging and mostly
supported by case reports/series and some large retrospective
analysis (Table 4). Although most cases usually present with
severe or very severe anemia requiring transfusion and prompt
intervention, a wait and see approach has also been used for
selected non-life-threatening cases with spontaneous recovery
in 80% of them.8 Concerning frontline therapy, the disease is
often resistant to steroids (ie, methylprednisolone 1–2 mg/day
IV), with response rates ranging from 10% to 55% and limited
benefit of high dose IVIGs addition (2 g/kg for 2 days).6–8,17–20
Table 3 Risk factors for the occurrence of post-transplant AIHA
Risk factor Estimated risk 95% CI P-value Reference
Unrelated donor 1.45 (Relative risk) 1.05–1.99 0.02 Sanz et al, BMT (2007)17
Unrelated donor 5.28 (Hazard risk) 1.22−22.9 0.026 Wang et al, Biol Blood Marrow Transplant (2015)6
HLA mismatch donor n.a. n.a. 0.005 González-Vicent et al, Transf Med Rev (2018)7
Development of chronic GVHD 12.17 (Relative risk) 96–1.54 0.018 Sanz et al, BMT (2007)17
Cord blood use n.a. n.a. 0.005 González-Vicent et al, Transf Med Rev (2018)7
Age <15 years n.a. n.a. 0.005 González-Vicent et al, Transf Med Rev (2018)7
CMV reactivation 3.4 (Hazard risk)a 1.2–9.6 0.02 Kruizinga et al, Biol Blood Marrow Transplant (2018)8
Alemtuzumab use 2.5 (Hazard risk)a 1.1–5.7 0.028 Kruizinga et al, Biol Blood Marrow Transplant (2018)8
Nonmalignant diagnosis pre-HSCT 3.5 (Hazard risk)a 1.1–10.9 0.031 Kruizinga et al, Biol Blood Marrow Transplant (2018)8
Notes: aRefers to all the autoimmune complications.
Factors not associated with post-BMT AIHA in different studies: 1) Wang et al.6 – recipient gender, primary hematological disease, source of hematopoietic stem cells,
conditioning regimen, HLA mismatch between donor and recipient, ABO antigen mismatch, recipient CMV status, and concurrent chronic GVHD. 2) González-Vicent et al.7
– acute GVHD. 3) Kruizinga et al.8 – gender, donor type, stem cell source, conditioning regimen, T cell depletion, GVHD prophylaxis, ATG serotherapy pre-HSCT, ABO
match, HLA mismatch, acute and chronic GVHD, EBV reactivation, adenovirus infection/reactivation, platelet recovery, absolute neutrophil count recovery, and chimerism in
peripheral blood mononuclear cells. 4) Sanz et al.17 – ex vivo T-cell depletion, CD3 dose, total-nucleated cell dose, ABO mismatch, CMV status (donor or recipient), GVHD
prophylaxis, acute GVHD.
Abbreviations: n.a. not available; AIHA, autoimmune hemolytic anemia.
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These response rates are clearly lower than those observed in
primary AIHA, suggesting a more profound immune dysre-
gulation in post-HSCTAIHA. As amatter of fact, most studies
did not take into account AIHA type, ie, wAIHA versus
cAIHA, which respond differently to steroids. However,
most post-HSCT cases are warm forms and cAIHA responds
to high steroid doses. Similarly, limited efficacy has been
obtainedwith plasma exchange, used for patients withmassive
hemolysis (ie, 1/10 cases); this treatment is recommended as
temporizing measure in primary AIHA, particularly in
cAIHA, given the predominant intravascular distribution of
IgM, before the immunosuppressive therapy takes effect.21,22
Historical second-line treatments were cytotoxic immunosup-
pressants, such as cyclophosphamide (ie, 800 mg IV), 6-mer-
captopurin (50 mg day) and mycophenolate mofetil (500 mg
BID), that induced heterogeneous response rates (9–
100%),7,18 with increased toxicity, similarly to what observed
for primary cases. Splenectomy has also been used with vari-
able response rates ranging from 0% to 100% (mean 39%),
again without distinguishing between warm and cold AIHA
type. Authors agree that splenectomy can be considered after
the 2nd line in selected wAIHA patients without
contraindications.6–8,17,23,24 Generally, with classical treat-
ments, most refractory cases died to opportunistic infections,
relapse of the primary disease and massive hemolysis.
Biological treatments for post-allo-
HSCTAIHA
The improving knowledge of AIHA pathogenesis has given
hints for a better therapeutic approach. AIHA is a heteroge-
neous disease mainly due to autoantibody-mediated destruc-
tion of erythrocytes but also involves dysregulation of
cellular and innate immunity with a well-established Th2
cytokine pattern. Moreover, complement activation and
defective bone marrow compensatory response play an
important role. Several drugs targeting these mechanisms
are under development in addition to standard therapies. In
particular, rituximab which acts on B-cells, bortezomib and
daratumumab targeting plasma cells, or sirolimus and abata-
cept directed against regulatory T-lymphocytes.1
Since the advent of biological target therapies, a signifi-
cant improvement of post-allo-HSCT AIHA outcome has
been observed. In particular, rituximab induced a response
in about 49% of cases in 2nd line (lower than in primary
AIHA), and in 88% of cases as 1st line, combined to steroid
treatment (comparable to primary cases), again without dis-
tinguishing for AIHA type.23–26 In particular, in a study by
Sanz et al, 3/4 cases responded to rituximab frontline (2 CR
and 1 PR), and 4/4 as second-line treatment (all PR).23 In
another study, Bhatt et al reported 100% responses in 9
patients (mostly adult) treated with rituximab 2–18 days
after diagnosis in combination with corticosteroids and
none died.24Moreover, Faraci et al observed 100% responses
to rituximab (all CR) in pediatric AIHA treated in first- (1
case) or second-line (7 cases).25 At variance, in a recent large
pediatric study including various autoimmune complications,
the majority of patients with AIHA did not have complete
response after treatment with steroids, IVIG and/or rituximab
requiring further lines of therapy.19 Overall, the introduction
of rituximab decreased mortality from 53% to 15%8 and
response to the drug established as a new prognostic factor
for post-HSCTAIHA. These data favor the use of rituximab
either frontline or as a step-up early second line in patients
with severe AIHA post-HSCT.
Few data are also available for the anti-CD52 MoAb
alemtuzumab targeting both B and T cells and resulting in
prolonged and profound lymphocytopenia. A combination
of lower-dose rituximab (100 mg IV weekly for 4 weeks)
and alemtuzumab (10 mg subcutaneously for 3 days)
induced 100% short-term response in 8 patients with pri-
mary AIHA, but only 3 cases maintained long-term
remission;27 2 patients have been treated after HSCT,
one responded28 and one not.7 Beyond efficacy, the severe
lymphoid suppression and increased risk of CMV reacti-
vation question the use of this antibody following HSCT
outside clinical trials.29
Another B-cell targeting agent is the proteasome inhi-
bitor bortezomib, the backbone therapy of multiple mye-
loma. The drug leads to the accumulation of
polyubiquitinated proteins, inducing the death of both
short- and long-lived plasma cells by activation of the
terminal-unfolded protein response. Bortezomib, at the
dose of 1.3 mg/sm IV single course, proof safe and effective
in case reports of secondary AIHA,29–31 and in a recent
Phase II prospective trial in primary cAIHA, with an overall
response of 31.6% (3 CR and 3 PR).32 Regarding post-
HSCTAIHA even higher responses were observed, overall
response of 58%, mostly as 3rd line in rituximab-refractory
cases.7,8,19,20,33–36 However, data come mainly from case
reports that carry the intrinsic bias of describing responding
patients only. In the HSCT setting, bortezomib will be
possibly used for GVHD prophylaxis in patients who
received HLA mismatched allogeneic HSCT, after its inhi-
bitory effect on alloreactive T cells and on T-helper 1 cells
that produce interferon-γ and IL-2.37
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Considering T-cell-directed drug used in AIHA, recent
attention has raised sirolimus, an inhibitor of the serine threo-
nine kinasemTOR (mammalianTargetOfRapamycin), part of
T-cell receptor downstream pathway, that regulates protein
synthesis, growth, proliferation, and activation of T cells.
Sirolimus has been reported to be effective in 80% of patients
with primary Evans syndrome, in 4 cases of pediatric patients
with multi-drug-refractory AIHA, and in 86% of 21 cases
following solid organ transplant.38–42 High efficacy has also
been reported in 6 multi-refractory post-HSCT AIHA case
reports, with the same caveat mentioned above. Finally, in
the recent pediatric series, sirolimus has been used in 2nd or
3rd line of therapy with good outcome.19 In this highly refrac-
tory life-threatening setting, sirolimus efficacy seems linked to
both the induction of abnormal T-cells apoptosis, and to the
increase of IL-10 and TGF-β secreting T-regulatory cells.
These additional mechanisms would target the residual “auto-
immunity triggering cells” spared after the treatment with
monoclonal antibodies.
Emerging treatments for post-allo-
HSCTAIHA
An emerging therapeutic target in AIHA is the complement
system, which plays a central role both in the intra- and in the
extravascular-mediated hemolysis. Complement blockade
reduces ongoing hemolysis, particularly in the acute phase.
Eculizumab, a humanized monoclonal antibody that binds to
the C5 fraction, has been successfully administrated to multi-
refractory primary AIHA patients, particularly in
cAIHA,43,44 with improvement in hemolysis (Hb increase
and LDH decrease with the reduction of transfusions in 7/13
cases) and clinical symptoms. In the post-HSCT setting,
responses are probably even lower, with only 1 of 3 reported
cases responding to 900 mg IV infusion.7,36 As a matter of
fact, the drug will only be effective on C5-mediated intra-
vascular hemolysis, that is marginal in the pathogenesis of
AIHA mainly encompassing earlier steps of the complement
cascade; moreover, it carries a significant infection risk,
particularly from meningococcal bacteria, that requires
appropriate vaccine schedules. New complement inhibitors
are under active study for primary and secondary AIHA,
including the IV C1s blocker sutimlimab, that induced sus-
tained responses in 7/10 cAIHA cases in Phase I,45–47 and the
subcutaneous C3 inhibitor APL-2 whose Phase II study is
currently ongoing.48
A further new drug that has recently shown efficacy in
AIHA is the anti-CD38 MoAb daratumumab, approved for
the treatment of multiple myeloma, but potentially target-
ing also CD38 expressing nonmalignant autoantibody-pro-
ducing plasma cells. A case report of efficacy in primary
AIHA has been recently published,49 moreover, 3 patients
with life-threatening post-transplant AIHA have also been
described, with complete and sustained response in 2
patients and a transient response in the other patient.
Importantly, the authors suggest that after depletion of B
and plasma cells by rituximab and daratumumab, immu-
noglobulin substitution should be administered in this set-
ting and B-cell reconstitution after drug administration is
variable.36
Finally, a recent study showed the efficacy of the T-cell
inhibitor abatacept in 3 post-allo-HSCT AIHA cases.50
Abatacept is a fusion protein formed by linking extracellular
domain of cytotoxic T-lymphocyte antigen 4 with the Fc
region of immunoglobulin G (IgG) and inhibits T-cell activa-
tion through competitive binding of CD80 and CD86 on
antigen-presenting cells, thus blocking the required CD28
costimulatory interaction. It is used for the treatment of
other autoimmune diseases including rheumatoid arthritis
and uveitis.51,52 The drug has also shown efficacy in acute
GVHD prophylaxis and has been demonstrated to increase T-
reg cells in one of the post-HSCTAIHA cases described.53
Transfusion issues
Supportive care with transfusions constitutes an important
component of the management of severe AIHA in post-
allo-HSCT setting. It is a common practice to give irra-
diated (25–30 Gy) and leuko-depleted RBC concentrates
in order to reduce potentially fatal transfusion reactions.
Since auto-antibodies are directed against highly prevalent
antigens, cross-matching is often unable to identify com-
patible RBC units.9 In any case, transfusions must not be
delayed in the acute setting since this option is lifesaving.
In life-threatening AIHA, transfusion with ABO, Rh and K
matched blood is more appropriate than waiting for full
compatibility investigations that can take 4–6 hrs or more.3
In less urgent cases, extended phenotyping is advisable in
order to provide the best matched RBC units. It is worth
reminding that transfusion may provoke alloantibody pro-
duction, an event observed in up to 30–40% of primary
AIHA cases, possibly causing serious acute or delayed
hemolytic transfusion reactions. Altogether, a close colla-
boration between clinicians, transfusion service and blood
bank is advisable for the best management of transfusion
support in post-allo-HSCT AIHA.
Dovepress Barcellini et al
Journal of Blood Medicine 2019:10 submit your manuscript | www.dovepress.com
DovePress
275
Conclusion
Post-allo-HSCT AIHA is definitely more severe and
refractory than primary forms. Moreover, it arises in a
complex and frail clinical context, marked by deep immu-
nosuppression and possible multi-organ failure. All these
factors lead to an increased mortality, which is hardly
attributable to AIHA itself, GVHD, or infectious compli-
cations. Main risk factors for the occurrence of AIHA are
unrelated donor and the development of chronic extensive
GVHD, highlighting the profound dysregulation of the
immunologic competence following allo-HSCT. CMV
reactivation has also been associated with post-HSCT
AIHA, in line with one of the mechanisms of the immu-
nologic tolerance breakdown, ie, molecular mimicry
between self-and foreign antigens. In addition, polyclonal
lymphocyte activation, which plays a key role in most
autoimmune conditions, certainly occurs after allo-HSCT,
which is definitely a major immunological “storm.” While
the degree of the immune activation is sometimes bene-
ficial (graft-versus-leukemia), it can be greatly harmful
(graft-versus-host), resembling in its chronic form a well-
known immune-mediated disease, ie, progressive systemic
sclerosis. Nonmalignant diagnosis pre-HSCT and alemtu-
zumab use have been implied too, although associated
with different types of autoimmune complications and
not specifically with AIHA.
Regarding therapy, steroids and rituximab, which are
now consolidated therapies for primary AIHAs, show an
unacceptable rate of failure in post-transplant forms, empha-
sizing the need for new-targeted therapies. The only satisfac-
tory results are those observed in front-line use of the two
drugs in combination, stressing the need for a prompt and
aggressive treatment of post-allo-HSCTAIHA. Among new
agents, either those mainly acting on plasma cells (bortezo-
mib and daratumumab), or targeting different T-lymphocyte
activation pathways (sirolimus and abatacept) or both (alem-
tuzumab), have shown promising results, although biased by
reporting successful cases only. A new class of inhibitors
would probably add powerful tools to the therapeutic arsenal
of post-HSCT AIHA, ie, the several agents acting on the
complement system. This would involve not only cAIHA,
where complement has a recognized pivotal role, but also
wAIHA, where its role is rather under-recognized but possi-
bly detrimental. Prospective controlled trials would be
obviously advisable, although difficult to conduct, given the
heterogeneity and relative rarity of post-allo-HSCT AIHA.
Most importantly, the understanding of the complex
immunological network and positive/negative interactions
occurring during immune-reconstitution will help in harnes-
sing the most appropriate therapy/association of drugs for
post-transplant AIHAs.
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